Capstone Holding Corp. filings document the regulatory record for a Nasdaq-listed emerging growth company operating a tech-enabled building products distribution platform. Its reports cover common stock listing details, convertible-note financing, working-capital and capital-structure disclosures, Regulation FD updates tied to investor FAQs and operating outlooks, and amendments to material-event reports.
Proxy and current-report filings address director elections, auditor ratification, a proposed reverse stock split authorization, related-party fee waiver and deferral arrangements, acquisition activity involving operating subsidiaries such as TotalStone and InStone Canada, delayed annual-report notice, and Nasdaq continued-listing matters.
Capstone Holding Corp. director Gordon Lewis Strout Jr reported multiple equity acquisitions in Capstone Holding Corp. common stock. On March 7, 2025, all Preferred Interests in TotalStone, LLC previously owned by him were exchanged under a Master Exchange Agreement for 822,128 shares of common stock held indirectly through Gordon Rocks, Inc. On March 7, 2025, he also purchased 41,500 common shares at $4.00 per share. In addition, he received unvested restricted stock awards of 142,500 shares on March 30, 2026 and 357,810 shares on August 7, 2026 for no consideration under the Capstone Holding Corp. 2025 Stock Incentive Plan; these restricted shares may not be sold, transferred, or pledged and will vest in full only upon his Separation Date as defined in his Master Restricted Stock Agreement.
Capstone Holding Corp. reported that director Michael Toporek acquired 1,094,647 shares of Common Stock on August 7, 2026 via a grant/award, not a market purchase. These shares are unvested restricted stock, granted for no consideration under the Capstone Holding Corp. 2025 Stock Incentive Plan, as amended.
The restricted stock may not be sold, transferred, or pledged and will vest in full only upon the Reporting Person's Separation Date, as defined in the Master Restricted Stock Agreement. Following this grant, Toporek directly holds 1,492,647 shares of Capstone Holding Corp. common stock.
Capstone Holding Corp. entered into a First Amendment with its institutional investor to its July 2025 senior secured convertible note, extending the note’s maturity date from July 29, 2026 to August 29, 2026. The amendment applies specifically to this July 2025 Convertible Note.
That note was issued on July 29, 2025 under a securities purchase agreement authorizing up to $10,909,885 in senior secured convertible notes, each issued with an 8.34% original issue discount. The July 2025 Convertible Note has an original principal amount of approximately $3,272,966.
TOPOREK MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Capstone Holding Corp. director Michael Toporek reported an amended grant of 356,250 shares of common stock as restricted stock awards on March 30, 2026, issued for no consideration. These shares vest only upon specified Board-related events, bringing his reported direct holdings to 391,678 shares, excluding 121,774 shares controlled through BP Peptides, LLC.
Capstone Holding Corp. director Michael Toporek purchased 41,750 shares of Common Stock on March 7, 2025 at $4.00 per share in a purchase in open market or private transaction. After this transaction, he directly holds 41,750 Capstone Holding Corp. Common Stock shares.
Capstone Holding Corp. director Michael Toporek reports his initial beneficial ownership, consisting entirely of indirect holdings. As of February 14, 2025, he controls 121,774 shares of Common Stock through BP Peptides, LLC and related entities, and an indirect warrant to purchase up to 6,322 shares of Common Stock at an exercise price of $75.00 per share, expiring on October 15, 2028. The warrant is held by Brookstone Partners IAC, Inc., investment manager to BP Peptides, LLC, which is controlled by Matthew Lipman and Michael Toporek.
Capstone Holding Corp. filed an initial insider report identifying Elwood D. Howse as a director of the company. This Form 3 submission lists no buy or sell transactions, no derivative transactions, and no specific holdings or derivative positions for him in this report.
Capstone Holding Corp. reports that Strout Gordon Lewis Jr is a reporting person in his capacity as a director through an initial Form 3 statement of beneficial ownership. The filing records no purchases, sales, derivative transactions, or holding entries in the company’s securities for him at this time.
Capstone Holding Corp. director and Chief Executive Officer Matthew E. Lipman reported purchasing 41,750 shares of Common Stock at $4.00 per share on March 7, 2025, increasing his direct holdings to 2,570,412 shares. The transaction is not designated under a Rule 10b5-1 trading plan.
Lipman Matthew E. reported acquisition or exercise transactions in this Form 4 filing.
Capstone Holding Corp. amended a prior insider report to clarify that Chief Executive Officer Matthew E. Lipman received a grant of 356,250 shares of common stock as restricted stock awards on March 30, 2026, vesting in full on March 30, 2029, for no consideration.
After this grant, he directly holds 2,920,340 shares of common stock. This figure excludes an additional 121,774 shares he controls through BP Peptides, LLC.